2004;17:167 71. 404. Steg PG, Mehta S, Jolly S, et al. Fondaparinux with UnfracTionated hep- arin dUring Revascularization in Acute coronary syndromes (FUTURA/ OASIS 8): a randomized trial of intravenous unfractionated heparin dur- ing percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Am Heart J. 2010;160:1029 34. 405. Montalescot G, Gallo R, White HD, et al. Enoxaparin versus unfraction- ated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009;2:1083 91. 406. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intra- venous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943 50. 407. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166 286. 408. Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation. 2005;112:1286 92. 409. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg. 2000;70:1986 90. 410. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309 17. 411. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol. 2008;52:1693 701. 412. Held C, Asenblad N, Bassand JP, et al. 